GSK Balancing Act: 9 Line Extensions In 2005-2007, 9 NMEs In 2006-2008
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GSK near-term pipeline remains dominated by line extensions, but firm hopes to offset with nine NME filings beginning in 2006. Upcoming filings include Wellbutrin XL for seasonal affective disorder and the Imitrex/naproxen migraine combo Trexima. CNS R&D presentation reflects focus on Phase II; oral multiple sclerosis agent is highlight